Toda, Japan

Satoru Misawa


Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Toda, JP (1996 - 1999)
  • Tokyo, JP (1999)

Company Filing History:


Years Active: 1996-1999

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Satoru Misawa: Innovator in Anticoagulant Research

Introduction

Satoru Misawa is a prominent inventor based in Toda, Japan, known for his significant contributions to the field of anticoagulant research. With a total of five patents to his name, he has made remarkable advancements in the development of hirudin analogs and their applications in medicine.

Latest Patents

Misawa's latest patents include innovative methods for manufacturing hirudin analogs and anticoagulant compositions. One of his notable inventions discloses hirudin analogs that feature specific amino acid substitutions to enhance stability and anti-thrombin activity. These modifications yield hirudin analogs with therapeutic potential as effective anticoagulants. Additionally, he has developed hirudin variants that exhibit high anti-thrombin and anti-platelet activity, along with methods for their production. These advancements are crucial for improving the efficacy of anticoagulant therapies.

Career Highlights

Throughout his career, Satoru Misawa has worked with reputable companies such as Japan Energy Corporation and Nippon Mining Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biochemistry and pharmaceutical innovations.

Collaborations

Misawa has collaborated with notable colleagues, including Hitoshi Matsuda and Akiko Sukesada. These partnerships have fostered a collaborative environment that enhances research and development in anticoagulant therapies.

Conclusion

Satoru Misawa's contributions to the field of anticoagulant research through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to impact the medical community positively, paving the way for advancements in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…